BACKGROUND: Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for Parkinson's disease (PD) and dementia with Lewy bodies (DLB). OBJECTIVE: We investigated the use of cardiac [123I]meta-iodo-benzyl-guanidine scintigraphy ([123I]MIBG) and olfactory testing- in comparison to [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single photon emission computed tomography ([123I]FP-CIT-SPECT)- for identifying iRBD patients as prodromal phenotype of PD/DLB. METHODS: 37 RBD subjects underwent cardiac [123I]MIBG and brain [123I]FP-CIT-SPECT at baseline. Olfactory (Sniffin' Sticks), cognitive and motor functions were tested annually for ∼4 years. RESULTS: 29/37 (78.4%) subjects had a pathological [123I]MIBG, of whom 86.2% (25/29) presented at least a moderate hyposmia at baseline (threshold/discrimination/identification-(TDI-)score ≤25). 20/37 (54.1%) subjects had a pathological [123I]FP-CIT-SPECT, always combined with a pathological [123I]MIBG. In subjects with pathological [123I]MIBG, olfactory function worsened (mainly due to threshold and discrimination subscores) from baseline to follow-up (p = 0.005). Olfaction was more impaired in subjects with pathological [123I]MIBG compared to those with normal [123I]MIBG at baseline (p = 0.001) and follow-up (p < 0.001). UPDRS-III scores increased in subjects with both pathological [123I]MIBG and [123I]FP-CIT-SPECT. In this group, seven subjects phenoconverted to PD, all- except for one- presented with at least moderate hyposmia at baseline. CONCLUSION: A combination of the biomarkers "pathological [123I]MIBG" and "hyposmia" likely identifies iRBD patients in an early prodromal stage of PD/DLB, i.e., before nigrostriatal degeneration is visualized. One-third of the subjects with pathological [123I]MIBG had a normal [123I]FP-CIT-SPECT. Noteworthy, in iRBD subjects with pathological [123I]MIBG, olfactory impairment is progressive independent of the [123I]FP-CIT-SPECT status.
BACKGROUND: Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for Parkinson's disease (PD) and dementia with Lewy bodies (DLB). OBJECTIVE: We investigated the use of cardiac [123I]meta-iodo-benzyl-guanidine scintigraphy ([123I]MIBG) and olfactory testing- in comparison to [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single photon emission computed tomography ([123I]FP-CIT-SPECT)- for identifying iRBD patients as prodromal phenotype of PD/DLB. METHODS: 37 RBD subjects underwent cardiac [123I]MIBG and brain [123I]FP-CIT-SPECT at baseline. Olfactory (Sniffin' Sticks), cognitive and motor functions were tested annually for ∼4 years. RESULTS: 29/37 (78.4%) subjects had a pathological [123I]MIBG, of whom 86.2% (25/29) presented at least a moderate hyposmia at baseline (threshold/discrimination/identification-(TDI-)score ≤25). 20/37 (54.1%) subjects had a pathological [123I]FP-CIT-SPECT, always combined with a pathological [123I]MIBG. In subjects with pathological [123I]MIBG, olfactory function worsened (mainly due to threshold and discrimination subscores) from baseline to follow-up (p = 0.005). Olfaction was more impaired in subjects with pathological [123I]MIBG compared to those with normal [123I]MIBG at baseline (p = 0.001) and follow-up (p < 0.001). UPDRS-III scores increased in subjects with both pathological [123I]MIBG and [123I]FP-CIT-SPECT. In this group, seven subjects phenoconverted to PD, all- except for one- presented with at least moderate hyposmia at baseline. CONCLUSION: A combination of the biomarkers "pathological [123I]MIBG" and "hyposmia" likely identifies iRBD patients in an early prodromal stage of PD/DLB, i.e., before nigrostriatal degeneration is visualized. One-third of the subjects with pathological [123I]MIBG had a normal [123I]FP-CIT-SPECT. Noteworthy, in iRBD subjects with pathological [123I]MIBG, olfactory impairment is progressive independent of the [123I]FP-CIT-SPECT status.
Authors: Jose-Alberto Palma; Clara Fernandez-Cordon; Elizabeth A Coon; Phillip A Low; Mitchell G Miglis; Safwan Jaradeh; Arijit K Bhaumik; Praveen Dayalu; Elena Urrestarazu; Jorge Iriarte; Italo Biaggioni; Horacio Kaufmann Journal: Clin Auton Res Date: 2015-03-05 Impact factor: 4.435
Authors: Ronald B Postuma; Jean-François Gagnon; Mélanie Vendette; Catherine Desjardins; Jacques Y Montplaisir Journal: Ann Neurol Date: 2011-01-18 Impact factor: 10.422
Authors: G Kobal; L Klimek; M Wolfensberger; H Gudziol; A Temmel; C M Owen; H Seeber; E Pauli; T Hummel Journal: Eur Arch Otorhinolaryngol Date: 2000 Impact factor: 2.503
Authors: Philipp Mahlknecht; Alex Iranzo; Birgit Högl; Birgit Frauscher; Christoph Müller; Joan Santamaría; Eduardo Tolosa; Monica Serradell; Thomas Mitterling; Viola Gschliesser; Georg Goebel; Florian Brugger; Christoph Scherfler; Werner Poewe; Klaus Seppi Journal: Neurology Date: 2015-01-21 Impact factor: 9.910
Authors: Jacob Horsager; Katrine B Andersen; Karoline Knudsen; Casper Skjærbæk; Tatyana D Fedorova; Niels Okkels; Eva Schaeffer; Sarah K Bonkat; Jacob Geday; Marit Otto; Michael Sommerauer; Erik H Danielsen; Einar Bech; Jonas Kraft; Ole L Munk; Sandra D Hansen; Nicola Pavese; Robert Göder; David J Brooks; Daniela Berg; Per Borghammer Journal: Brain Date: 2020-10-01 Impact factor: 13.501